Renovo (RenovoRx Nasdaq: RNXT), is a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform. Oncologist is an international peer-reviewed Journal for practicing oncologists and hematologists.
Behind all this biotech is a very good therapy with potential to lower deadly numbers of Pancreatic Cancer. Targeting Pancreatic Cancer, which has a 5-year survival rate of 13% (and that’s stage 1-4). That is 18 percent of patients a year. Moreover, 13% will not survive past five tears. As we all know, Pancreatic cancer is a nasty, nasty disease. (Previous article)
Average survival rate is 3.5 years. If the disease is note dealt with, Pancreatic cancer can go from stage one to stage four in a year. Survival is basically nil. The work of RenovoRx is obvious and a possible scourge of this killer.
Recently the Company increased production of its FD cleared RevenoCath due to medical need for targeted therapeutic/drug delivery from Oncologists. Delivery is based on the Company’s Local Drug Delivery Program (LAPD). Progress continues with the Company’s previous announced Trans-Arterial Micro-Perfusion (TAMP) therapy platform. The chart shows active shares even in the reality of low volume. Volatility on low volume be you friend. Sometimes.
Leesa Gentry, Chief Clinical Officer of RenovoRx, commented, “As we continue to make steady progress with our pivotal Phase III trial in LAPC, we have received feedback from oncology and interventional radiology physicians and key opinion leaders expressing the desire to purchase RenovoCath as a standalone device to be used in clinical practice. RenovoCath has been used in over 500 procedures by interventionalists over the past several years. We have published data from completed early-stage clinical trials that highlight the potential benefits to patients receiving targeted therapy with RenovoCath, including less toxicity and better outcomes, over the current standard of care.”
Cancer Research UK Stats
So as one can see, the odds are not in the least in the patients’ corner. Current therapies for this horrible and usually fatal disease; “Resectable (surgical removeable) pancreatic tumours can be completely removed with surgery. Stage 1 or 2 tumours are often resectable. They are treated with surgery to remove part, or all, of the pancreas. Chemotherapy may be given after surgery (called adjuvant chemotherapy). If cancer cells are found in the tissue removed along with the tumour during surgery (called positive surgical margins), radiation therapy or chemoradiation may be given. (Canadian Cancer Society)
RNXT’s therapy is quite ingenious and seems to have caught the attention of the FDA and its ilk for perhaps fast tract approval. Obviously, doctors and patients are keen to utilize the therapy.
RenovoRx The therapeutic approach of TAMP is specifically designed for the localized and targeted delivery of chemotherapy via the peripheral vascular system. Our patented delivery system is inserted into an artery that runs adjacent to the tumor via an approximately 4 mm incision made in the patient’s leg. RenovoCath’s double balloon design enables the physician to isolate sections of the blood vessel through the adjustment of the distance between the balloons, thereby excluding any side branches in order to create the pressure head needed to push chemotherapy across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy.
Liver cancer tumors are highly vascularized and typically have large tumor feeders or blood vessels connected to the tumor, making them better candidates for systemic chemotherapy because medicine is able to gain direct access to the tumor. In contrast, pancreatic cancer tumors lack visible tumor feeder blood vessels, which means the chemotherapy circulates through the body, without a significant amount of medicine reaching the tumor.
To sum up, RNXT manages to ‘bathe’ the tumor in chemotherapy as opposed to the kind of hit and miss of chemo alone. The recurrence of tumours is also quite likely and due the fact of a lack of blood vessels in a pancreatic tumour, the RNXT’s approach seems to have merit and promise.
This therapy and RNXT other research will eventually be applicable to many cancers and are in various stages of regulatory, Phase studies and development, evidencing what could be a page turner in the cancer scourge, particularly the almost always lethal pancreatic.
Likely a place in your holdings should be allocated.
Here’s RNXT’s roundup of therapies, studies, etc.
